Efficacy of combination therapy in rheumatoid arthritis: Comment on the review by Smolen et al [3]

Arthritis and Rheumatism

Volumn 54, Issue 6, 2006, Pages 2032-2034

  Möttönen, Timo ^a   Hannonen, Pekka ^b   Leirisalo Repo, Marjatta ^c   Korpela, Markku ^d   Hakala, Markku ^e   Kautiainen, Hannu ^e  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

^b JYVÄSKYLÄ CENTRAL HOSPITAL   (Finland)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^d TAMPERE UNIVERSITY HOSPITAL   (Finland)

^e RHEUMATISM FOUNDATION HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; HYDROXYCHLOROQUINE; METHOTREXATE; PREDNISOLONE; SALAZOSULFAPYRIDINE;

DISEASE ACTIVITY; DRUG EFFICACY; HUMAN; JOINT DESTRUCTION; LETTER; PRIORITY JOURNAL; REMISSION; RHEUMATOID ARTHRITIS;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG THERAPY, COMBINATION; HUMANS;

EID: 33745035862     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.21915     Document Type: Letter

References (11)

1. Smolen JS, Aletaha D, Keystone E. Superior efficacy of combination therapy for rheumatoid arthritis: fact or fiction? [review]. Arthritis Rheum 2005;52:2975-83.
2. Mottonen T, Hannonen P, Leirisalo-Repo M, Nissila M, Kautiainen H, Korpela M, et al, and the FIN-RACo Trial Group. Comparison of the combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. Lancet 1999;353:1568-73.
3. Neva M, Kauppi MJ, Kautiainen H, Luukkainen R, Hannonen P, Leirisalo-Repo M, et al, for the FIN-RACo Trial Group. Combination drug therapy retards the development of rheumatoid atlantoaxial subluxations. Arthritis Rheum 2000;43:2397-401.
4. Puolakka K, Kautiainen H, Mottonen T, Hannonen P, Korpela M, Julkunen H, et al, for the FIN-RACo Trial Group. Impact of initial aggressive drug treatment with a combination of disease-modifying antirheumatic drugs on development of work disability in early rheumatoid arthritis: a five-year randomized followup trial. Arthritis Rheum 2004;50:55-62.
5. Korpela M, Laasonen L, Hannonen P, Kautiainen H, Leirisalo-Repo M, Hakala M, et al, for the FIN-RACo Trial Group. Retardation of joint damage in patients with early rheumatoid arthritis by initial aggressive treatment with disease-modifying antirheumatic drugs: five-year experience from the FIN-RACo study. Arthritis Rheum 2004;50:2072-81.
6. Puolakka K, Kautiainen H, Mottonen T, Hannonen P, Korpela M, Hakala M, et al, for the FIN-RACo Trial Group. Early suppression of disease activity is essential for maintenance of work capacity in patients with recent-onset rheumatoid arthritis: a five-year experience from the FIN-RACo trial Arthritis Rheum 2005;52:36-41.
7. Larsen A, Dale K, Eek M. Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films. Acta Radiol 1977;18:481-91.
8. Mottonen T, Hannonen P, Leirisalo-Repo M, Nissila M, Kautiainen H, and the FIN-RACo Trial Group. Combination therapy in rheumatoid arthritis [letter]. Lancet 1999;354:952-3.
9. O'Dell JR, Leff R, Paulsen G, Haire C, Mallek J, Eckhoff PJ, et al. Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002;46:1164-70.
10. Calguneri M, Pay S, Caliskaner Z, Apras S, Kiraz S, Ertenli J, et al. Combination therapy versus monotherapy for the treatment of patients with rheumatoid arthritis. Clin Exp Rheumatol 1999;17:699-704.
11. Dougados M, Combe B, Cantagrel A, Goupille P, Olive P, Schattenkirchner M, et al. Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components. Ann Rheum Dis 1999;58:220-5.